Denmark’s Zealand Pharma A/S has raised DKK 492.5 million ($78.3 million) from its previously announced initial public share offering on Nasdaq in the US. The goal is to support the clinical development of two of its peptide therapeutics. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals